Get the Stockscreener App
10.28
1.96%
-0.205
Ars Pharmaceuticals Inc stock is traded at $10.28, with a volume of 674.48K.
It is down -1.96% in the last 24 hours and down -16.53% over the past month.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
See More
Previous Close:
$10.48
Open:
$10.5
24h Volume:
674.48K
Relative Volume:
0.55
Market Cap:
$1.02B
Revenue:
-
Net Income/Loss:
$-44.84M
P/E Ratio:
-21.86
EPS:
-0.47
Net Cash Flow:
$-44.23M
1W Performance:
-5.12%
1M Performance:
-16.53%
6M Performance:
-13.94%
1Y Performance:
+17.97%
1-Day Range:
$10.24
$10.64
1-Week Range:
$10.02
$11.01
52-Week Range:
$7.55
$18.51
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
Name
Ars Pharmaceuticals Inc
Sector
Industry
Phone
858-771-9307
Address
11682 EL CAMINO REAL, SUITE 120, SAN DIEGO
Compare SPRY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SPRY
Ars Pharmaceuticals Inc
|
10.28 | 1.02B | 0 | -44.84M | -44.23M | -0.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
490.05 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
688.27 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
632.13 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.34 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
112.82 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-10-25 | Initiated | Oppenheimer | Outperform |
| Aug-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-13-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-12-24 | Reiterated | Leerink Partners | Outperform |
| Jul-25-24 | Initiated | Raymond James | Outperform |
| Mar-05-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-20-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Sep-20-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jan-31-23 | Initiated | Wedbush | Outperform |
| Jan-03-23 | Initiated | William Blair | Outperform |
| Dec-13-22 | Initiated | SVB Leerink | Outperform |
View All
Ars Pharmaceuticals Inc Stock (SPRY) Latest News
Levi & Korsinsky, LLP Investigates Possible Securities Fraud Violations by ARS Pharmaceuticals, Inc. (SPRY) - ACCESS Newswire
ARS Pharmaceuticals' (SPRY) "Outperform" Rating Reaffirmed at William Blair - MarketBeat
Allspring Global Investments Holdings LLC Increases Stock Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - MarketBeat
ARS Pharmaceuticals (SPRY) Stock Price, News & Analysis - MarketBeat
ARS Pharmaceuticals (NASDAQ:SPRY) Earns Outperform Rating from William Blair - Defense World
(SPRY) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Allspring Global Investments Holdings LLC Has $3.63 Million Stock Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World
Levi & Korsinsky Reminds Shareholders of an Investigation into ARS Pharmaceuticals, Inc. (SPRY) Regarding Potential Securities Fraud Allegations - ACCESS Newswire
Revolutionary Allergy Spray Gets Massive Insurance Breakthrough: Now Covered for Half of US Patients - StockTitan
ARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and Navitus Health Systems Add neffy® ... - The Bakersfield Californian
ARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and - GlobeNewswire
Peregrine Capital Management LLC Invests $4.47 Million in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - MarketBeat
ARS Pharmaceuticals Presents Data On Neffy Epinephrine Nasal Spray At 2025 AAAAI Meeting - Nasdaq
ARS Pharmaceuticals to Showcase Innovation and Present Data - GlobeNewswire
ARS Pharmaceuticals to Showcase Innovation and Present Data on neffy® (epinephrine nasal spray) ... - The Bakersfield Californian
Revolutionary Needle-Free Allergy Treatment Shows Superior Results: Clinical Data Reveals Game-Changing Efficacy - StockTitan
U.S. Inflation Readings Show Pick Up in Pricing Pressures - The Globe and Mail
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Gap UpHere's What Happened - MarketBeat
Oppenheimer Initiates Coverage on ARS Pharmaceuticals (NASDAQ:SPRY) - MarketBeat
(SPRY) Technical Data - Stock Traders Daily
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Sells $615,500.00 in Stock - MarketBeat
ARS Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Conference - GlobeNewswire
ARS Pharmaceuticals' Neffy Launch Could Be A Hit For Severe Allergic Reactions - Seeking Alpha
Allergy Treatment Pioneer ARS Pharmaceuticals Takes Center Stage at Major Healthcare Conference - StockTitan
Ars Pharmaceuticals director Laura Shawver sells $615k in stock - MSN
Ars Pharmaceuticals director Laura Shawver sells $615k in stock By Investing.com - Investing.com Australia
ARS Pharma Rolls Dice Again On NeffyWill Persistence Pay Off? - RTTNews
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Down 5.3%What's Next? - MarketBeat
3 US Growth Stocks With Significant Insider Ownership - Simply Wall St
(SPRY) Investment Report - Stock Traders Daily
ARS Pharmaceuticals (NASDAQ:SPRY) Trading 5.4% HigherStill a Buy? - MarketBeat
Allegations Against ARS Pharmaceuticals, Inc.: Schall Law Firm Initiates Investigation And Encourages Impacted Investors To Reach Out - ACCESS Newswire
ARS Being Investigated on Behalf of ARS Pharmaceuticals, Inc. Investors. Contact Levi & Korsinsky For Details - ACCESS Newswire
Neffy Launches Free Epi Nasal Sprayer Program for U.S. Schools - Allergic Living
Equities Analysts Issue Forecasts for SPRY FY2025 Earnings - MarketBeat
What is William Blair's Estimate for SPRY FY2024 Earnings? - MarketBeat
William Blair Has Bullish Forecast for SPRY Q4 Earnings - MarketBeat
ARS Pharmaceuticals Launches neffyinSchools Program - GlobeNewswire
ARS Pharmaceuticals lays down 2025 objectives for epinephrine nasal spray - MSN
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Holdings Lessened by ARS Investment Partners LLC - MarketBeat
ARS Pharmaceuticals Launches neffyinSchools Program Providing Free Life-Saving Needle-Free Epinephrine For Emergency Use to Eligible K-12 Schools - The Manila Times
ARS Pharma Launches Free Neffy Nasal Spray Program for U.S. Schools to Combat Allergic Reactions - StockTitan
When (SPRY) Moves Investors should Listen - Stock Traders Daily
Analysts Set ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Target Price at $26.00 - MarketBeat
Raymond James Issues Positive Forecast for ARS Pharmaceuticals (NASDAQ:SPRY) Stock Price - MarketBeat
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Gap Up on Analyst Upgrade - MarketBeat
Ars Pharmaceuticals Inc Stock (SPRY) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.34%
1.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):